mmtc archived content

Translational Medicine - Completing the Circle: Bedside Back to Bench

 

Short Courses |  Day 1 | Day 2 | Day 3Download Brochure

Wednesday, February 3

7:00 AM Registration and Morning Coffee

Plenary Keynote Session

8:10 When Drug Research is Personal

John F. Crowley, Founder, Novazyme Pharmaceuticals, Inc.

Mr. Crowley’s emotion-packed presentation will focus on his personal struggle to find a cure for Pompe disease, a rare and fatal illness that is caused by a defective or missing enzyme. Pompe disease affects fewer than 10,000 people world-wide, including Mr. Crowley’s two small children. Mr. Crowley, a Harvard educated businessman, created and built a pharmaceutical company devoted expressly to finding a cure for the disease. He will detail his journey through the labyrinth of scientific and business fronts, which lead up to a first-round clinical trial.

8:55 Technology, Aging, and the Brain

Gary W. Small, M.D., Parlow-Solomon Professor on Aging, Professor of Psychiatry & Biobehavioral Sciences, Director, UCLA Center on Aging, Director, Memory & Aging Research Center, Director, Geriatric Psychiatry Division, Semel Institute for Neuroscience & Human Behavior, David Geffen School of Medicine at UCLA

New neuroimaging and other technologies are teaching us about how the brain ages and what we can do about it. Although memory declines as we age, medical and nonpharmacological strategies may protect brain health and improve memory performance. At the same time, innovation in digital technology is not only changing the way we live and communicate, it appears to be altering how our brains function. As a consequence of this high-tech stimulation, we are witnessing the beginning of a new form of the generation gap – a brain gap dividing younger digital natives, immersed in the technology early in life, from older digital immigrants, who adapt to the new technology more reluctantly. This lecture will describe this current pivotal point in brain evolution and how we can harness the new technology and lifestyle choices to improve memory and brain function so we can live better and longer. 

9:40 Grand Opening Refreshment Break in the Exhibit Hall

 

TRENDS IN TRANSLATIONAL MEDICINE

11:00 Chairperson’s Remarks

Christina M. Coughlin, M.D., Ph.D., Medical Director, Oncology Clinical Research and Development, Wyeth Research

11:10 Translational Approach to Studying Stroke

Giora Z. Feuerstein, M.D., Assistant VP, Discovery Translational Medicine, Wyeth Research Labs

 To improve success of clinical trials and speed drug development, departments of Translational Medicine in pharma have formed to figure out the which molecular, biochemical and physiological biomarkers can best substitute for the absence of cinical outcome studies. My presentation will illustrate how we've applied a translational approach to develop better therapies for stroke. Specifically we've focused on reducing attrition rate of compounds/biologicals by optimizing 1. Target Validation; 2. Compound -Target interaction; 3. innovative Pharmacokinetic-Pharmacodynamic and proof of Mechanism of Action (MoA); 4. disease biomarkers; 5. Patient selections for clinical trials based on evidence for likelihood to respond to treatment.

11:40 Contribution of Translational Approaches to Recent Advances in Immuno-therapeutics, Immuno-rejection and Beyond

Francesco Marincola, M.D., Chief, Infectious Disease and Immunogenetics Section, NIH; Editor in Chief, Journal of Translational Medicine

 The complexity underlying a pathological process does not necessarily require complex solutions. The biology determining allograft or cancer rejection, autoimmunity or tissue damage during pathogen infections is complex; however, common patterns are emerging that lead to a common final outcome: tissue destruction with resolution of the pathogenic process (cancer, infection) or tissue damage and organ failure (allograft rejection, autoimmunity). Human observations based on transcriptional profiling converge into an “immunological constant of rejection” that signals such occurrences. This constant includes the coordinate activation of interferon stimulated genes (ISGs) and immune effector functions (IEFs). Understanding this final effector pathway may suggest novel strategies for the induction or inhibition of tissue-specific destruction with therapeutic intent in cancer and other immune pathologies. This presentation will discuss how vaccines may play a role in tissue-specific destruction and use this as a model to demonstrate how to understand the dynamics of therapeutics by studying target tissues in real time.

12:10 PM Panel: Practical Translational Medicine

Moderator: Vivek Kadambi, Ph.D., Senior Director, Millenium Pharmaceuticals

  • When to use biomarkers for go/no-go decisions on proceeding with development of a clinical compound
  • How has translational medicine changed over the past 5 years?
  • Fostering partnerships between industry, academics and government granting institutions
  • How are pharmaco-dynamic and predictive markers being used right now in clinical development?

Panelists: Giora Z. Feuerstein, M.D., Assistant Vice President and Head, Discovery Translational Medicine, Wyeth Research Labs

Lise Kjems, M.D., Ph.D., Executive Director, Global Program DiagnosticDirector, Molecular Diagnostics Novartis 

Francesco Marincola, M.D., Chief, Infectious Disease and Immunogenetics Section, NIH; Editor-in-Chief, Journal of Translational Medicine

William B. Mattes, PhD, DABT, PharmPoint Consulting, Former Executive Director, Predictive Safety Testing Consortium 
Yali Fu, Ph.D., Program Director, Grants and Contracts Operations Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute
Hans Winkler, Ph.D., Senior Director, Global Head Oncology Biomarkers, Johnson & Johnson

Sponsored by

12:40 Luncheon Presentation I

ZDSD Rat:  A Model for Diabetes, Metabolic Syndrome, and Obesity without Leptin or Leptin Receptor Mutations

Richard G. Peterson, Ph.D.; Executive VP Research & Development, PreClinOmics, Inc.

  • The ZDSD rat is a model for obesity, insulin resistance, metabolic syndrome and diabetes with a normal leptin axis.
  • The disease conditions expressed in the ZDSD more closely resemble the human situation when compared to other animal models.
  • The obesity and diabetes in the ZDSD rat can be modulated with diet.
  • The obesity and diabetes in the ZDSD rat can be treated with standard pharmaceuticals.
  • The ZDSD rat expresses the bone, renal and other complications seen in diabetes.

1:10 Luncheon Presentation II (Sponsorship Opportunity Available)

1:45 Dessert in the Exhibit Hall

 

WORKING BACKWARDS IN CANCER:
From the Clinic to Discovery

2:15 Chairperson’s Remarks

Michael Liebman, Ph.D., Managing Director, Strategic Medicine, Inc.

2:20 Using Drug-Induced Feedback Loops to Identify Indications and Combination Partners

Donald Bergstrom, Ph.D., Director, Experimental Medicine Oncology, Merck

James W. Watters, Ph.D., Associate Director, Molecular Profiling Oncology, Merck

Treatment with molecular targeted agents can result in compensatory feedback regulation as cells respond to inhibition of signaling pathways. We will present clinical evidence that treatment with a small molecule inhibitor of gamma secretase results in pathway modulation and compensatory feedback, and describe pre-clinical experiments designed to leverage this concept for drug response prediction.

3:00 Moving Research Closer to the Bedside, in Vitro and in Vivo Analyses with Primary Tumors

Fred Poordad, M.D., Chief of Hepatology, Liver Disease and Transplant Center, Cedars-Sinai Medical Center; Xin Wei Wang, Ph.D., Senior Investigator, Head, Liver Carcinogenesis Section, Laboratory of Human Carcinogenesis, National Cancer Institute, NIH; Michael R. Briggs, Ph.D., Senior Director, Biology, Vertex Pharmaceuticals, Inc.

The incidence of Primary Liver Cancer is increasing in the west and constitutes a tremendous burden on world health as the third leading cause of cancer deaths worldwide. The 5 year survival rate is a dismal 11 %, due in large part to late diagnosis and limited treatment options. The etiology of this devastating disease as well as current and proposed new therapies will be discussed. Steps to better diagnose and stratify patients for targeted therapy will be considered as a new and exciting phase of cancer research. Finally, a move toward more relevant research will be presented as an hypothesis that will be tested in the coming years as more new and current therapies are compared and contrasted to current best practice.

4:05 How Do You Go From Pathways to Clinical Outcomes?

Aris Persidis, Ph.D., President, Biovista, Inc.

In drug discovery and development what what really counts is the clinical outcome, the Benefit/Risk of the drug within the context of its pathway or mechanism of action (MoA). Biovista screens the MoA of any drug or target against the MoA of 8,000 indications and 12,000 adverse events (AEs). This is simultaneous, unbiased indication discovery and AE profiling, and it is unique. It helps to bridge the gap from molecular pathway to clinical outcome in a single step. Case studies in cancer and other diseases will be described.

Sponsored by

4:35 Reception in the Exhibit Hall (Sponsorship Available)l

5:20 BREAK-OUT DISCUSSIONS in the Exhibit Hall
1. Novel Imaging Biomarkers in Drug Development

Moderator: Jingsong Wang, M.D., Director of Immunology, Discovery Medicine & Clinical Pharmacology, Bristol-Myers Squibb, Co.

  • The distinct advantage and unique challenges in applying imaging biomarkers in drug development

  • The most promising novel imaging biomarkers for drug development, and which therapeutic areas will benefit the most from using imaging biomarker

  • The role of pharmaceutical company, CRO, academia and regulatory agency in the discovery, development and qualification of imaging biomarkers

2. Biomarkers in Translational Medicine

Co-Moderators:
Christina M. Coughlin, M.D., Ph.D.; Medical Director, Oncology; Clinical Research and Development; Pfizer Oncology
Hans Winkler, Ph.D., Senior Director, Global Head Oncology Biomarkers, Johnson & Johnson 

  • Which type of biomarkers will speed drug development the most?

  • Predictive marker clinical validation: retrospective vs. prospective trial requirements

  • Do we still need phamaco dynamic analysis in Phase II?

3. New Funding Opportunities for Biotechs 

Moderator:
Yali Fu, Ph.D., Program Director, Grants and Contracts Operations Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute

  • Understand NIH Enhanced Peer Review

  • NCI’s new initiatives on SBIR funding

  • Phase II Bridge awards to help biotechs further develop their technologies

4. New Animal Models in Translational Medicine

  • Ideal characteristics for new animal models

  • Advantages of new animal models

  • Designing studies and using new animal models in discovery research

Co-Moderators: 
Richard G. Peterson, Ph.D., Professor Emeritus, Indiana University School of Medicine and EVP, Research and Development PreClinOmics, Inc.
Troy A. Gobbett, MS, Director, Sales & Marketing for PreClinOmics,Inc.

6:20 Close of Day

 

Short Courses |  Day 1 | Day 2 | Day 3Download Brochure

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

 

2015 Brochure cover 

Premier Sponsors:

Abbott Molecular 

 

Elsevier  


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Silicon Biosystems 

 

Singulex 

Thomson Reuters-Large